Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients von YOVINE, A, RIOFRIO, M, CVITKOVIC, E, MISSET, J. L, BLAY, J. Y, BRAIN, E, ALEXANDRE, J, KAHATT, C, TAAMMA, A, JIMENO, J, MARTIN, C, SALHI, Y

Volltext

Oxaliplatin: A review of preclinical and clinical studies von Raymond, E., Chaney, S. G., Taamma, A., Cvitkovic, E.

Volltext

Ongoing and unsaid on oxaliplatin: the hope von Cvitkovic, E

Volltext

Phase II Study of Oxaliplatin, Fluorouracil, and Folinic Acid in Locally Advanced or Metastatic Gastric Cancer Patients von LOUVET, C, ANDRE, T, ROUGIER, P, CVITKOVIC, E, DE GRAMONT, A, TIGAUD, J. M, GAMELIN, E, DOUILLARD, J. Y, BRUNET, R, FRANCOIS, E, JACOB, J. H, LEVOIR, D, TAAMMA, A

Volltext

Single agent and combination studies of pralatrexate and molecular correlates of sensitivity von Serova, M, Bieche, I, Sablin, M-P, Pronk, G J, Vidaud, M, Cvitkovic, E, Faivre, S, Raymond, E

Volltext

Gemcitabine Combined With Oxaliplatin in Advanced Pancreatic Adenocarcinoma: Final Results of a GERCOR Multicenter Phase II Study von Louvet, C.

Volltext

Cumulative toxicities from cisplatin therapy and current cytoprotective measures von Cvitkovic, E.

Volltext

Ecteinascidin-743: A Marine-Derived Compound in Advanced, Pretreated Sarcoma Patients—Preliminary Evidence of Activity von DELALOGE, S, YOVINE, A, MARTY, M, CVITKOVIC, E, TAAMMA, A, RIOFRIO, M, BRAIN, E, RAYMOND, E, COTTU, P, GOLDWASSER, F, JIMENO, J, MISSET, J. L

Volltext

568 The BET bromodomain inhibitor OTX015 shows synergy with several anticancer agents in preclinical models of mantle cell lymphoma (MCL) and multiple myeloma (MM) von Bernasconi, E, Tarantelli, C, Gaudio, E, Kwee, I, Stathis, A, Riveiro, E, Herait, P, Cvitkovic, E, Zucca, E, Bertoni, F

Volltext

565 Preclinical evaluation of OTX015, a novel BET-BRD inhibitor, on small cell lung cancer (SCLC) cell lines von Ijaz, N, Astorgues-Xerri, L, Odore, E, Bekradda, M, Cvitkovic, E, Noel, K, Raymond, E, Riveiro, M

Volltext

567 OTX015, a BET-bromodomain (BET-BRD) inhibitor, potentiates the in vitro effects of chemotherapy drugs and targeted agents in human leukemic cell lines von Astorgues-Xerri, L, Canet-Jourdan, C, Bekradda, M, Cvitkovic, E, Herait, P, Raymond, E, Riveiro, M

Volltext

469 OTX015, a novel BET-bromodomain (BET-BRD) inhibitor, is a promising anticancer agent for human glioblastoma von Ouafik, L, Berenguer, C, Cayol, M, Astorgues-Xerri, L, Bekradda, M, Odore, E, Rezai, K, Riveiro, M.E, Cvitkovic, E

Volltext

587 Cellular pharmacokinetics and molecular pharmacodynamics studies of the BRD-BET inhibitor OTX015 in sensitive and resistant leukemic cell lines von Odore, E, Astorgues-Xerri, L, Bekradda, M, Cvitkovic, E, Herait, P, Lokiec, F, Rezai, K, Riveiro, M

Volltext

Phase I and Pharmacokinetic Study of Ecteinascidin-743, a New Marine Compound, Administered as a 24-hour Continuous Infusion in Patients With Solid Tumors von TAAMMA, A, MISSET, J. L, RIOFRIO, M, GUZMAN, C, BRAIN, E, LOPEZ LAZARO, L, ROSING, H, JIMENO, J. M, CVITKOVIC, E

Volltext

580 Evaluation of the pan-BET-bromodomain inhibitor OTX015 as a single agent and in combination with everolimus (RAD001) in triple-negative breast cancer models von Vázquez, R, Astorgues-Xerri, L, Riveiro, M.E, Di Marino, M, Beltrame, L, Bekradda, M, Cvitkovic, E, Erba, E, Frapolli, R, D'Incalci, M

Volltext

564 OTX015, a novel BET-BRD inhibitor is active in non-small-cell lung cancer cell (NSCLC) lines harboring different oncogenic mutations von Riveiro, M, Astorgues-Xerri, L, Ijaz, N, Bekradda, M, Vazquez, R, Frapolli, R, Rinaldi, A, Kwee, I, Cvitkovic, E, Raymond, E

Volltext

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells von Benhadji, K A, Serova, M, Ghoul, A, Cvitkovic, E, Le Tourneau, C, Ogbourne, S M, Lokiec, F, Calvo, F, Hammel, P, Faivre, S, Raymond, E

Volltext

Antiproliferative effects of sapacitabine (CYC682), a novel 2′-deoxycytidine-derivative, in human cancer cells von SEROVA, M, GALMARINI, C. M, RAYMOND, E, GHOUL, A, BENHADJI, K, GREEN, S. R, CHIAO, J, FAIVRE, S, CVITKOVIC, E, LE TOURNEAU, C, CALVO, F

Volltext

Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients von Ducreux, M., Mitry, E., Ould-Kaci, M., Boige, V., Seitz, J. F., Bugat, R., Breau, J. L., Bouché, O., Etienne, P. L., Tigaud, J. M., Morvan, F., Cvitkovic, E., Rougier, P.

Volltext

Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports von Wasserman, E., Myara, A., Lokiec, F., Goldwasser, F., Trivin, F., Mahjoubi, M., Misset, J. L., Cvitkovic, E.

Volltext